drugset / Trial / NCT04552769

Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

NCT04552769

Phase 2 Completed 9 enrolled Stanford University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the efficacy of treatment with abemaciclib in patients with anaplastic thyroid/undifferentiated thyroid

Timeline

Start
2020-09-10
Primary completion
2023-04-12
Completion
2025-01-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Abemaciclib Small molecule 200 mg Oral